MONT-SAINT-GUIBERT, Belgium, November 21, 2013 /PRNewswire/ --
The Belgian biotechnology company Cardio3 BioSciences (C3BS)(NYSE Euronext Brussels and Paris : CARD), leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, is pleased to announce that it has won the Trends-Tendances Business Tour 2013 Award in the "Innovation" category for Wallonia.
This award was presented this Wednesday, November 20, 2013 at an awards ceremony for the Trends Tendances Business Tour 2013 Wallonia.
The Trends-Tendances Business Tour is an initiative from the magazine and its Dutch counterpart Trends, in collaboration with Wallonia Foreign Trade & Investment Agency (AWEX) and Business & Society. The Business Tour showcases three companies in three different fields: sustainable management, export and innovation. The choice of these iconic companies in their field was made by the editors of the magazine and BDO, partner of the event.
Cardio3 BioSciences' most advanced therapy, C-Cure®, involves taking cells from a patient's bone marrow and through a proprietary process called Cardiopoiesis re-programming those cells so that they become heart precursor cells. The cells, known as cardiopoietic cells, are then injected back into the patient's heart through a minimally invasive procedure using a proprietary catheter called C-Cathez® with the goal of repairing damaged tissue and improving heart function, clinical outcomes and quality of life. C-Cure® is in a Phase III clinical trial in Europe. The trial, called CHART-1, represents the world's first Phase III trial for a pre-programmed cellular therapy targeting heart failure.
C-Cure® builds on research conducted at Mayo Clinic (Rochester, Minnesota, USA), Cardio3 BioSciences (Mont-Saint-Guibert, Belgium) and Cardiovascular Centre Aalst (Aalst, Belgium).
Dr Christian Homsy, CEO of Cardio3 BioSciences, said: "We are very proud and honored to win the Trends-Tendances Business Tour Award for the most innovative company in Wallonia. We have been developing an alternative approach to medicine for many years. Together with the other players in regenerative medicine, we are inventing a new industry, a new medical approach and bringing new hope for patients. We hope that this recognition also serves the other companies in this field in the Walloon Region and allows us to consolidate the leadership of our region in the highly specialized field of regenerative medicine."
About Cardio3 BioSciences
Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.
The Company's lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle cells that behave identically to those lost to heart disease. This process is known as Cardiopoiesis.
Cardio3 BioSciences has also developed C-Cath®ez, the most technologically injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.
Cardio3 BioSciences' shares are listed on NYSE Euronext Brussels and NYSE Euronext Paris under the ticker symbol CARD.
C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both.
SOURCE Cardio3 BioSciences